Arcus Biosciences [RCUS] vs Vertex [VRTX] Detailed Stock Comparison

Arcus Biosciences Inc.

NYSE
Loading...

Vertex Pharmaceuticals Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Arcus Biosciences Inc. wins in 2 metrics, Vertex Pharmaceuticals Inc. wins in 15 metrics, with 0 ties. Vertex Pharmaceuticals Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Arcus Biosciences Inc. Vertex Pharmaceuticals Inc. Better
P/E Ratio (TTM) N/A 28.40 N/A
Price-to-Book Ratio 4.99 5.92 Arcus Biosciences Inc.
Debt-to-Equity Ratio 34.71 10.91 Vertex Pharmaceuticals Inc.
PEG Ratio -7.12 0.88 Vertex Pharmaceuticals Inc.
EV/EBITDA -6.35 21.78 Vertex Pharmaceuticals Inc.
Profit Margin (TTM) -142.92% 32.94% Vertex Pharmaceuticals Inc.
Operating Margin (TTM) -345.45% 39.60% Vertex Pharmaceuticals Inc.
EBITDA Margin (TTM) N/A 39.60% N/A
Return on Equity -63.26% 22.54% Vertex Pharmaceuticals Inc.
Return on Assets (TTM) -21.08% 12.16% Vertex Pharmaceuticals Inc.
Free Cash Flow (TTM) $-484.00M $3.19B Vertex Pharmaceuticals Inc.
1-Year Return 183.76% 1.24% Arcus Biosciences Inc.
Price-to-Sales Ratio (TTM) 12.78 9.22 Vertex Pharmaceuticals Inc.
Enterprise Value $2.39B $105.96B Vertex Pharmaceuticals Inc.
EV/Revenue Ratio 9.67 8.83 Vertex Pharmaceuticals Inc.
Gross Profit Margin (TTM) N/A 85.39% N/A
Revenue per Share (TTM) $2 $47 Vertex Pharmaceuticals Inc.
Earnings per Share (Diluted) $-3.29 $15.32 Vertex Pharmaceuticals Inc.
Beta (Stock Volatility) 0.86 0.37 Vertex Pharmaceuticals Inc.
Short % of Float 11.16% 1.78% Vertex Pharmaceuticals Inc.

Arcus Biosciences Inc. vs Vertex Pharmaceuticals Inc. Stock Performance Analysis

Loading Price Chart...

RCUS
VRTX

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Arcus Biosciences Inc.-2.49%-0.46%-8.41%6.38%-6.91%2.45%
Vertex Pharmaceuticals Inc.0.76%-2.03%-0.35%-9.68%-7.51%-5.26%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Arcus Biosciences Inc.183.76%20.61%1.16%43.98%43.98%43.98%
Vertex Pharmaceuticals Inc.1.24%34.08%113.19%376.31%717.28%1,190.86%

Performance & Financial Health Analysis: Arcus Biosciences Inc. vs Vertex Pharmaceuticals Inc.

MetricRCUSVRTX
Market Information
Market Cap i$3.20B$109.45B
Market Cap CategoryMid capLarge cap
10 Day Avg. Volume i1,560,5831,057,061
90 Day Avg. Volume i1,285,6911,272,097
Last Close$23.86$428.34
52 Week Range$7.91 - $28.72$362.50 - $507.92
% from 52W High-16.92%-15.67%
All-Time High$49.10 (Nov 22, 2021)$519.88 (Nov 04, 2024)
% from All-Time High-51.41%-17.61%
Growth Metrics
Quarterly Revenue Growth0.27%0.10%
Quarterly Earnings Growth0.27%0.31%
Financial Health
Profit Margin (TTM) i-1.43%0.33%
Operating Margin (TTM) i-3.45%0.40%
Return on Equity (TTM) i-0.63%0.23%
Debt to Equity (MRQ) i34.7110.91
Cash & Liquidity
Book Value per Share (MRQ)$5.04$73.49
Cash per Share (MRQ)$7.83$26.01
Operating Cash Flow (TTM) i$-482,000,000$3.63B
Levered Free Cash Flow (TTM) i$-162,250,000$2.57B
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Arcus Biosciences Inc. vs Vertex Pharmaceuticals Inc.

MetricRCUS (Apr 26, 2026)VRTX (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) iN/A28.40
Forward P/E i-7.1219.95
PEG Ratio i-7.120.88
Price to Sales (TTM) i12.789.22
Price to Book (MRQ) i4.995.92
Market Capitalization
Market Capitalization i$3.20B$109.45B
Enterprise Value i$2.39B$105.96B
Enterprise Value Metrics
Enterprise to Revenue i9.678.83
Enterprise to EBITDA i-6.3521.78
Risk & Other Metrics
Beta i0.860.37
Book Value per Share (MRQ) i$5.04$73.49

Financial Statements Comparison: Arcus Biosciences Inc. vs Vertex Pharmaceuticals Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricRCUS (2025)VRTX (2025)
Revenue/Sales i247.00M12.00B
Cost of Goods Sold iN/A1.65B
COGS % of Revenue i0.0%13.8%
Gross Profit iN/A10.35B
Gross Margin i0.0%86.2%
Research & Development i523.00M4.04B
Operating Income (EBIT) i-386.00M4.55B
Operating Margin i-156.3%37.9%
EBITDA i-335.00M5.25B
EBITDA Margin i-135.6%43.7%
Pre-Tax Income i-353.00M4.64B
Pre-Tax Income % of Revenue i-142.9%38.7%
Income Tax i0690.00M
Income Tax % of Revenue i0.0%5.7%
Net Income (Profit) i-353.00M3.95B
Profit Margin i-142.9%32.9%

Balance Sheet & Liquidity Metrics

MetricRCUS (2025)VRTX (2025)
Cash & Equivalents i222.00M5.08B
Total Current Assets i1.01B11.20B
Total Current Assets % of Revenue i407.7%93.3%
Total Current Liabilities i231.00M3.86B
Total Current Liabilities % of Revenue i93.5%32.2%
Long-Term Debt i99.00M1.95B
Long-Term Debt % of Revenue i40.1%16.3%
Total Shareholders Equity i631.00M18.67B
Retained Earnings i-1.49B13.56B
Retained Earnings % of Revenue i-601.2%113.0%
Property, Plant & Equipment i28.00M1.56B

Cash Flow Statement Comparison

MetricRCUS (2025)VRTX (2025)
Operating Cash Flow i-469.00M3.77B
Operating Cash Flow % of Revenue i-189.9%31.4%
Capital Expenditures i-2.00M-437.60M
Free Cash Flow i-484.00M3.19B
FCF Margin i-196.0%26.6%
Debt Repayment iN/A-5.40M
Common Stock Repurchase iN/A-2.39B

Short Interest & Institutional Ownership Analysis

MetricRCUSVRTX
Shares Short i9.88M4.02M
Short Ratio i7.592.80
Short % of Float i11.16%1.78%
Shares Outstanding i125.30M253.99M
Float Shares i88.65M253.24M
% Held by Insiders i29.17%0.21%
% Held by Institutions i74.41%97.60%
% Held by Public i-3.58%2.19%

Dividend Analysis & Yield Comparison: Arcus Biosciences Inc. vs Vertex Pharmaceuticals Inc.

MetricRCUSVRTX
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A